DGIdb - PAZOPANIB Drug Record

PAZOPANIB chembl:CHEMBL477772 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PAZOPANIB
GW786034
VOTRIENT
GW 78603
INDAZOLYLPYRIMIDINE 13
GW 786034
PZP034
chembl:CHEMBL477772
chemidplus:444731-52-6
drugbank:06589
pubchem.compound:10113978
rxcui:714438

Drug Info:

FDA Approval	Renal cell carcinoma
Drug Class	Kinase Inhibitors
FDA Approval	approved
Drug Class	small molecule
Drug Indications	antineoplastic agent

(9 More Sources)

Publications:

Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep
Maitland ML et al., 2015, Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib., Clin Cancer Res
Xu F et al., 2013, Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II., Eur J Med Chem
Grande E et al., 2015, Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)., Ann Oncol
Ravi V et al., 2016, Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib., J Natl Compr Canc Netw
Subbiah V et al., 2017, Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma., Clin Cancer Res
Xu CF et al., 2016, HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer., Clin Cancer Res
Motzer RJ et al., 2013, Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms., Ann Oncol
Ball et al., 2015, Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer., Oncol. Rep.
Malchers F et al., 2014, Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer., Cancer Discov
Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov
Koehler et al., 2016, TP53 mutational status is predictive of pazopanib response in advanced sarcomas., Ann. Oncol.
Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.
Wu et al., 2013, Identification of targetable FGFR gene fusions in diverse cancers., Cancer Discov
Deeks, 2012, Pazopanib: in advanced soft tissue sarcoma., Drugs
Sethakorn N et al., 2016, Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma., BJU Int
Borad et al., 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma., PLoS Genet.
Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.
Pick AM et al., 2012, Pazopanib for the treatment of metastatic renal cell carcinoma., Clin Ther
Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol

PAZOPANIB HLA-B

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26546620

Sources:
PharmGKB FDA
PAZOPANIB UGT1A1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family VEGFR inhibitor

Alteration UGT1A1:.

PMIDs:
24107802

Sources:
CGI PharmGKB FDA
PAZOPANIB FLT4

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Pazopanib

Notes

PMIDs:
17288876 28377484 27160228

Sources:
TALC MyCancerGenome TdgClinicalTrial CIViC GuideToPharmacology MyCancerGenomeClinicalTrial
PAZOPANIB KDR

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Pazopanib

Novel drug target Established target

Notes

PMIDs:
17288876 25411163 24036042 26063633 27160228

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial CIViC GuideToPharmacology MyCancerGenomeClinicalTrial PharmGKB
PAZOPANIB FLT1

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial GuideToPharmacology MyCancerGenomeClinicalTrial
PAZOPANIB FGFR3

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
23558953 23072642 27271022

Sources:
JAX-CKB CIViC
PAZOPANIB FGFR2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status case report

Pathway activation

Variant Effect gain-of-function

PMIDs:
24550739 23786770

Sources:
DoCM CIViC
PAZOPANIB PDGFRB

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome GuideToPharmacology MyCancerGenomeClinicalTrial
PAZOPANIB PDGFRA

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial
PAZOPANIB CYP2C8

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25504632

Sources:
PharmGKB
PAZOPANIB KIT

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
17288876

Sources:
TALC MyCancerGenome GuideToPharmacology MyCancerGenomeClinicalTrial
PAZOPANIB NEK2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB TNK2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB NF1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Pazopanib

Drug family MTOR inhibitor;VEGFR inhibitor

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
PAZOPANIB HDAC2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28221861

Sources:
CIViC
PAZOPANIB FGFR1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
24302556

Sources:
DTC CIViC GuideToPharmacology
PAZOPANIB LIMK1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB LTK

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB CDK7

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB PTK2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB CSF1R

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
DTC GuideToPharmacology
PAZOPANIB TAOK1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB ABCG2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25504632

Sources:
PharmGKB
PAZOPANIB MAPK9

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB FYN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB MAP4K4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB IGF1R

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB MAPK8

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB AURKA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB ALK

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB LCK

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB AURKB

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24625776

Sources:
CIViC
PAZOPANIB KRAS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
26324075

Sources:
JAX-CKB
PAZOPANIB RET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pazopanib + Vorinostat

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

PMIDs:
26646755 25669829

Sources:
JAX-CKB CIViC
PAZOPANIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB PPARD

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB YES1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22341567

Sources:
PharmGKB
PAZOPANIB AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: PAZOPANIB
- Version: 20-Jun-2017
Alternate Names:

PAZOPANIB Generic Name

VOTRIENT Trade Name

Drug Info:

Drug Class Kinase Inhibitors

FDA Approval Renal cell carcinoma

Publications:
TdgClinicalTrial: PAZOPANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval approved

Publications:

DTC: PAZOPANIB

Version: 02-September-2020

Alternate Names:

CHEMBL477772 ChEMBL Drug ID

Drug Info:

Publications:

Xu F et al., 2013, Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II., Eur J Med Chem

JAX-CKB: Pazopanib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Ball et al., 2015, Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer., Oncol. Rep.

Wu et al., 2013, Identification of targetable FGFR gene fusions in diverse cancers., Cancer Discov

Koehler et al., 2016, TP53 mutational status is predictive of pazopanib response in advanced sarcomas., Ann. Oncol.

DoCM: PAZOPANIB
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.

PharmGKB: pazopanib

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther

Maitland ML et al., 2015, Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib., Clin Cancer Res

Xu CF et al., 2016, HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer., Clin Cancer Res

CIViC: PAZOPANIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Liao et al., 2013, Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma., Cancer Res.

Borad et al., 2014, Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma., PLoS Genet.

Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.

TALC: PAZOPANIB
- Version: 12-May-2016
Alternate Names:

GW786035 Drug Synonym

GW786036 Drug Synonym

GW786037 Drug Synonym

Drug Info:

Publications:
GuideToPharmacology: 178102325
- Version: 29-September-2020
Alternate Names:

PAZOPANIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
CGI: Pazopanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL477772
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: PAZOPANIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
FDA: Pazopanib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Notes
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Indication/Tumor Type	urinary bladder cancer
Response Type	sensitive
Approval Status	Preclinical

Clinical Status	case report
Pathway	activation
Variant Effect	gain-of-function

combination therapy	Everolimus;Pazopanib
Drug family	MTOR inhibitor;VEGFR inhibitor
Alteration	NF1:.

Indication/Tumor Type	thyroid cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

combination therapy	Pazopanib + Vorinostat
Indication/Tumor Type	Advanced Solid Tumor
Response Type	decreased response

GW786035	Drug Synonym
GW786036	Drug Synonym
GW786037	Drug Synonym

Novel drug target	Established target
Trial Name	Pazopanib
Notes

Trial Name	Pazopanib
Novel drug target	Established target
Notes

PAZOPANIB Drug Record

PAZOPANIB chembl:CHEMBL477772 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26546620

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Drug family VEGFR inhibitor Alteration UGT1A1:.

PMIDs: 24107802

Sources: CGI PharmGKB FDA

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Pazopanib Notes

PMIDs: 17288876 28377484 27160228

Sources: TALC MyCancerGenome TdgClinicalTrial CIViC GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Pazopanib Novel drug target Established target Notes

PMIDs: 17288876 25411163 24036042 26063633 27160228

Sources: TALC DTC MyCancerGenome TdgClinicalTrial CIViC GuideToPharmacology MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 17288876

Sources: TALC DTC MyCancerGenome TdgClinicalTrial GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type urinary bladder cancer Response Type sensitive Approval Status Preclinical

PMIDs: 23558953 23072642 27271022

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Clinical Status case report Pathway activation Variant Effect gain-of-function

PMIDs: 24550739 23786770

Sources: DoCM CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 17288876

Sources: TALC DTC MyCancerGenome GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 17288876

Sources: TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25504632

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 17288876

Sources: TALC MyCancerGenome GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus;Pazopanib Drug family MTOR inhibitor;VEGFR inhibitor Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28221861

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: 24302556

Sources: DTC CIViC GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
26546620

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family VEGFR inhibitor

Alteration UGT1A1:.

PMIDs:
24107802

Sources:
CGI PharmGKB FDA

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Pazopanib

Notes

PMIDs:
17288876 28377484 27160228

Sources:
TALC MyCancerGenome TdgClinicalTrial CIViC GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Pazopanib

Novel drug target Established target

Notes

PMIDs:
17288876 25411163 24036042 26063633 27160228

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial CIViC GuideToPharmacology MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
23558953 23072642 27271022

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status case report

Pathway activation

Variant Effect gain-of-function

PMIDs:
24550739 23786770

Sources:
DoCM CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
25504632

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
17288876

Sources:
TALC MyCancerGenome GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Pazopanib

Drug family MTOR inhibitor;VEGFR inhibitor

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
28221861

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
24302556

Sources:
DTC CIViC GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
DTC GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25504632